Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0D0DR
|
||||
| Former ID |
DNC010802
|
||||
| Drug Name |
1-(3-(4-fluorophenyl)propyl)-1H-imidazole
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [528335] | ||
| Formula |
C12H13FN2
|
||||
| Canonical SMILES |
C1=CC(=CC=C1CCCN2C=CN=C2)F
|
||||
| InChI |
1S/C12H13FN2/c13-12-5-3-11(4-6-12)2-1-8-15-9-7-14-10-15/h3-7,9-10H,1-2,8H2
|
||||
| InChIKey |
BEKCOALNZLRGJA-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | 17 alpha-hydroxylase-C17, 20-lyase | Target Info | Inhibitor | [528335] | |
| Cytochrome P450 19 | Target Info | Inhibitor | [530867] | ||
| NetPath Pathway | FSH Signaling Pathway | ||||
| PANTHER Pathway | Androgen/estrogene/progesterone biosynthesis | ||||
| WikiPathways | Metapathway biotransformation | ||||
| Steroid Biosynthesis | |||||
| Oxidation by Cytochrome P450 | |||||
| Metabolism of steroid hormones and vitamin D | |||||
| Glucocorticoid & Mineralcorticoid Metabolism | |||||
| Prostate Cancer | |||||
| Phase 1 - Functionalization of compoundsWP702:Metapathway biotransformation | |||||
| Tryptophan metabolism | |||||
| Ovarian Infertility Genes | |||||
| FSH signaling pathway | |||||
| Integrated Breast Cancer Pathway | |||||
| Phase 1 - Functionalization of compounds | |||||
| References | |||||
| Ref 528335 | Bioorg Med Chem Lett. 2006 Sep 15;16(18):4752-6. Epub 2006 Jul 25.Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)). | ||||
| Ref 530867 | Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. Epub 2010 Apr 8.Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). | ||||